PATENT APPLICATIONS

PATENT APPLICATIONS

2016   PCT/GB2017/051379 Bioorthogonal prodrugs (University of Edinburgh). Priority date: 29/04/2016.

2015   PCT/GB2016/051057 Compounds (University of Edinburgh). Priority date: 21/05/2015. National filing (2009): US, Europe, Japan, China & Canada. GRANTED in US

 

2014   PCT/ES2015/070203 Purine Derivatives as DAPK1 Inhibitors (Universidad de Granada & University of Edinburgh). Priority date: 25/03/2014. GRANTED in Spain

 

2013   PCT/GB2014/051894 Bioorthogonal Methods and Prodrugs (University of Edinburgh). Priority date: 21/06/2013. National filing (2015): US and Europe.

 

2010   PCT/GB2011/000749 Cationic Lipids (University of Edinburgh). Priority date: 18/05/2010. National filing (2011): US (US8759104 B2, granted) and Europe (EP2571527; pending). —Licensed to DELIVERICS

 

2007   PCT/GB2008/003527 Cationic Lipids (University of Edinburgh). Priority date: 19/10/2007. National filing (2009): US, Europe, India, Japan, Australia & Canada. —Licensed to DELIVERICS

PRODUCT COMMERCIALIZATION

2016-       Highly-selective mTOR Inhibitor eCF309 sold globally by Axon Medchem (Netherlands)

 

2010-14   SAFEctin Transfection Reagent and SAFEctin STEM licensed and produced by Deliverics Ltd (UK) and distributed by Albyn Medical (Spain), CoreSciences (South Korea) and Galen Lab (USA)  

STARTUPS / SPIN-OUT COMPANIES

2015-      THER-IP LTD (SC499733)

2010-16   DELIVERICS LIMITED (SC377672)

Provider of easy-to-use kits for delivering biomolecules into and onto cells

RESEARCH COLLABORATIONS WITH PHARMA

2017-      Merck & Co. through a MRS Award

© 2019 by Asier Unciti-Broceta. Proudly created with Wix.com
 

  • Twitter Classic
  • Facebook Classic